Toronto: In a new breakthrough in cancer treatment, University of Montreal Hospital Research Centre (CRCHUM) researchers have developed an injectable 'biogel' that can effectively deliver anti-cancer agents directly into tumours and kill them.
The technology has already been successfully tested in the laboratory. If it works in patients, the therapy could one day revolutionize treatment for many forms of cancer.
The new biogel is liquid at room temperature and gels at 37 degrees Celsius - human body temperature.
"The strength of this biogel is that it is compatible with anti-cancer immune cells. It is used to encapsulate these cells and eventually administer them using a syringe or catheter into the tumour or directly beside it," explained study co-author Rejean Lapointe.
"Instead of injecting these cells or anti-cancer drugs throughout the entire body via the bloodstream, we can treat the cancer locally. We hope that this targeted approach will improve current immunotherapies," Lapointe added.
The anti-cancer immune cells, called T-cells, are produced naturally by the body and have the ability to destroy cancer cells, but they are generally too weak and too few to eradicate the cancer alone.
T cells are therefore cultivated in the laboratory -- often the patient's own cells - and then reinjected into the patient's blood.
While this form of immunotherapy has shown promising results in cases of advanced cancer, it is not always possible to generate enough T cells.
"With our technique, we only need to administer a few dozen million T cells, instead of the billions currently required. We can also administer compounds that 'awaken' the immune system to fight against cancer," Lapointe explained.
The study was published in the journal Biomaterials.
The technology has already been successfully tested in the laboratory. If it works in patients, the therapy could one day revolutionize treatment for many forms of cancer.
The new biogel is liquid at room temperature and gels at 37 degrees Celsius - human body temperature.
"Instead of injecting these cells or anti-cancer drugs throughout the entire body via the bloodstream, we can treat the cancer locally. We hope that this targeted approach will improve current immunotherapies," Lapointe added.
Advertisement
T cells are therefore cultivated in the laboratory -- often the patient's own cells - and then reinjected into the patient's blood.
Advertisement
"With our technique, we only need to administer a few dozen million T cells, instead of the billions currently required. We can also administer compounds that 'awaken' the immune system to fight against cancer," Lapointe explained.
Advertisement
COMMENTS
Advertisement
Cancers In Head And Neck Rising, Account For 26% Cases In India: Study Cancer Cases Rising, Prices Of Essential Medicines Kept In Check: Health Minister China Man With Cough For Over 2 Years Discovers It Was Caused By Chilli Pepper 3 Students Dead After Flooding In Delhi Coaching Centre Basement At Olympics Opening Ceremony, Drag Parody Of 'The Last Supper' Draws Flak Children Of Indian-Americans Face Deportation As Time Runs Out Kamala Harris Says "Underdog" Campaign Will Overcome Trump's "Wild Lies" President Appoints 6 New Governors, Reshuffles 3 Others Bomb Threat Inside Delhi Bus, Police Recover Suspicious Object Track Latest News Live on NDTV.com and get news updates from India and around the world.